Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Enecadin is an inhibitor of voltage-gated sodium channels (Navs) and high-voltage activated calcium channels.1 It selectively inhibits Navs and L-, N-, and T-type calcium channels over voltage-gated potassium channels in NG 108-15 cells (IC50s = 7.8, 4.5, 7.3, 17.2, and 160.5 µM, respectively). In vivo, enecadin (0.125-0.5 mg/kg, i.v.) reduces infarct volume and improves motor incoordination in a rat model of stroke induced by permanent middle cerebral artery occlusion (MCAO).2 It also reduces neuronal necrosis in a rabbit model of spinal cord ischemia when administered at a dose of 1 mg/kg.3
WARNING This product is not for human or veterinary use.
1. Na+ and high-
2. Cerebroprotective action of a Na+/Ca2+ channel blocker NS-
3. NS-